Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Activation of androgen receptor (AR) may have a role in the development of castration-resistant prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in castrated animals. However, the upstream signals that activate these kinases and lead to AR activation are incompletely characterized. In this study, we investigated AR phosphorylation in response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6. Small interfering RNA-mediated knockdown of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation, whereas Src mediates Tyr-534 phosphorylation induced by EGF, IL-6 and bombesin. Dasatinib, a Src inhibitor, blocked EGF-induced Tyr-534 phosphorylation. In addition, we showed that dasatinib also inhibited Ack1 kinase. Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib may exert antitumor activity in prostate cancer through inhibition of Ack1.
Liu
Y
Y
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA.
Karaca
M
M
Zhang
Z
Z
Gioeli
D
D
Earp
H S
HS
Whang
Y E
YE
D059002:Androgen Receptor Antagonists; D000818:Animals; D019556:COS Cells; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D000069439:Dasatinib; D006801:Humans; D015151:Immunoblotting; D008297:Male; D051379:Mice; D010766:Phosphorylation / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013844:Thiazoles / Q000494:pharmacology*; D014162:Transfection; D023041:Xenograft Model Antitumor Assays; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
C410798:AR protein, human; D059002:Androgen Receptor Antagonists; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011944:Receptors, Androgen; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; C403262:TNK2 protein, human; D019061:src-Family Kinases; D000069439:Dasatinib
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6
16247015
Mol Cell Biol. 2001 Dec;21(24):8385-97
11713275
Cancer Res. 2006 Nov 15;66(22):11047-54
17108144
Br J Cancer. 2006 Jan 30;94(2):318-22
16421597
Oncogene. 2006 Mar 30;25(14):2011-21
16434977
Mol Endocrinol. 2006 Mar;20(3):503-15
16282370
Cancer Res. 2001 Apr 1;61(7):2892-8
11306464
Int J Cancer. 2009 Jan 1;124(1):1-6
18942061
J Biol Chem. 2002 Mar 1;277(9):7076-85
11751884
Cancer Cell. 2006 Oct;10(4):309-19
17045208
J Clin Oncol. 2005 Nov 10;23(32):8253-61
16278481
Cancer Res. 1998 Dec 15;58(24):5718-24
9865729
Curr Cancer Drug Targets. 2007 Sep;7(6):591-604
17896924
Cancer Res. 2005 Apr 15;65(8):3404-9
15833875
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6
16046538
Cancer Res. 2005 Nov 15;65(22):10514-23
16288044
J Biol Chem. 2002 Aug 9;277(32):29304-14
12015328
Endocrinology. 2000 Dec;141(12):4698-710
11108285
J Biol Chem. 2008 Jul 25;283(30):20989-1001
18511414
Clin Cancer Res. 2008 Jan 15;14(2):352-9
18223208
Nat Med. 1997 Apr;3(4):402-8
9095173
Cancer Cell. 2004 Nov;6(5):517-27
15542435
Cancer Res. 2009 Jan 1;69(1):151-60
19117998
J Biol Chem. 2002 Oct 11;277(41):38087-94
12163482
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9796-801
16777958
Nat Med. 2004 Jan;10(1):33-9
14702632
Cancer Res. 2009 Sep 15;69(18):7402-11
19706771
J Biol Chem. 2009 Dec 11;284(50):34954-63
19815557
J Biol Chem. 2004 Feb 20;279(8):7119-30
14662770
Cancer Res. 2006 Nov 1;66(21):10449-59
17079466
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43
17494760
Clin Cancer Res. 2009 Dec 1;15(23):7421-8
19920114
Clin Cancer Res. 2005 Mar 1;11(5):1704-12
15755991
Cancer Res. 2008 May 1;68(9):3323-33
18451159